SCHEDULE 13D/A: Major Shareholder Updates Outlook Therapeutics Stake to 41.6% Following Corporate Charter Amendment
Beneficial Ownership Update
GMS Ventures and Ghiath M. Sukhtian have updated their beneficial ownership in Outlook Therapeutics, Inc. to 41.6% following an amendment to the Issuer's Restated Certificate of Incorporation.
Summary
- This filing is Amendment No. 4 to the Schedule 13D originally filed by GMS Ventures and Ghiath M. Sukhtian regarding their beneficial ownership in Outlook Therapeutics, Inc.
- The amendment reports changes in beneficial ownership due to the approval of an amendment to Outlook Therapeutics' Restated Certificate of Incorporation.
- As of March 11, 2025, GMS Ventures and Ghiath M. Sukhtian collectively beneficially own 16,183,787 shares of Outlook Therapeutics common stock.
- This represents approximately 41.6% of the outstanding shares, calculated based on 32,017,179 shares outstanding as of January 24, 2025, plus 3,458,571 Tranche A Inducement Warrants and 3,458,571 Tranche B Inducement Warrants.
- GMS Ventures directly holds 9,266,645 common shares and 6,917,142 warrants to purchase shares.
- Ghiath M. Sukhtian is deemed to beneficially own the securities held by GMS Ventures due to a controlling interest in GMS Holdings, which is the sole owner of GMS Ventures.
Sentiment
Score: 5
Explanation: This is a neutral, factual disclosure of beneficial ownership changes, not containing positive or negative performance indicators or forward-looking statements that would influence sentiment.
Future Outlook
NA
Industry Context
NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Amendment to Restated Certificate of Incorporation | The filing reports changes in beneficial ownership of shares of Outlook Therapeutics, Inc. as a result of the approval of an amendment to the Issuer's Restated Certificate of Incorporation. | NA | This amendment led to a recalculation of beneficial ownership for the reporting persons, resulting in their reported stake of 41.6%. |
Stakeholder Impact
- Shareholders: Provides updated transparency on the significant beneficial ownership stake held by GMS Ventures and Ghiath M. Sukhtian, which could reinforce perceptions of control and stability by a major investor.
Key Dates
| Date | Description |
|---|---|
| December 30, 2019 | Date of Power of Attorney by Ghiath M. Sukhtian. |
| January 29, 2020 | Date of Form 4 filing by Ghiath M. Sukhtian (referenced for Power of Attorney). |
| February 25, 2020 | Date of Power of Attorney by GMS Ventures and Investments. |
| February 27, 2020 | Date of Form 3 filing by GMS Ventures and Investments (referenced for Power of Attorney). |
| April 21, 2022 | Date of Amended & Restated Investor Rights Agreement between Outlook Therapeutics, Inc. and GMS Ventures and Investments. |
| April 22, 2022 | Date of Issuer's Form 8-K filing (referenced for Investor Rights Agreement). |
| July 7, 2022 | Original Statement on Schedule 13D filed with the SEC. |
| December 29, 2022 | Amendment No. 1 to Schedule 13D filed with the SEC. |
| March 20, 2024 | Amendment No. 2 to Schedule 13D filed with the SEC. |
| January 16, 2025 | Date of Form of Inducement Letter and Form of Common Stock Purchase Warrants. |
| January 22, 2025 | Amendment No. 3 to Schedule 13D filed with the SEC. |
| January 24, 2025 | Date as of which 32,017,179 outstanding shares of the Issuer were reported in the Issuer's Registration Statement on Form S-3. |
| February 28, 2025 | Date of Issuer's Registration Statement on Form S-3 filed with the SEC. |
| March 11, 2025 | Date of event which requires filing of this Amendment No. 4 to Schedule 13D. |
| March 12, 2025 | Date of execution of the Joint Filing Agreement and signing of the Schedule 13D/A. |
Keywords
Outlook Therapeutics, GMS Ventures, Ghiath M. Sukhtian, Schedule 13D/A, Beneficial Ownership, Common Stock, SEC Filing, Corporate Governance, Warrants
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.